8-K: Silexion Therapeutics Faces Nasdaq Delisting Threat, Plans Reverse Stock Split

Silexion Therapeutics Corp received a Nasdaq notice for failing to meet the minimum bid price requirement and plans a 1-for-15 reverse share split to regain compliance.

Summary

• Silexion Therapeutics Corp (SLXN) received a Nasdaq notice on July 18, 2025, for its ordinary shares trading below the minimum $1.00 bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
• The Nasdaq hearings panel will consider this bid price deficiency in its decision regarding the company's continued listing.
• The company's ordinary shares and warrants (SLXNW) continue to trade on the Nasdaq Capital Market without immediate effect on listing.
• A Nasdaq hearings panel previously ruled on July 7, 2025, that the company's listing remains intact, subject to certain conditions.
• To remedy the bid price deficiency, the company intends to effect a 1-for-15 reverse share split, which was approved by shareholders on July 14, 2025.
• The reverse share split will be effective after the close of trading on July 28, 2025, with trading on a split-adjusted basis beginning July 29, 2025.
• The company expects to regain compliance with the bid price requirement after a minimum of 10 consecutive trading days if the price remains above $1.00.
• The company must also achieve at least $2.5 million of shareholders' equity and meet the Nasdaq Equity Standard by September 19, 2025.

Sentiment

Score: 3

Explanation: The company is facing a significant compliance issue with Nasdaq, including a bid price deficiency and a requirement to meet an equity standard. While a plan is in place (reverse split), there are explicit risks of not achieving or maintaining compliance, which could lead to delisting. This indicates a negative outlook, though the existence of a plan prevents a score of 1 or 2.

Positives

• The company's securities listing on Nasdaq remains intact, subject to fulfillment of certain conditions, following a favorable decision from a Nasdaq hearings panel on July 7, 2025.
• The company has a clear plan (1-for-15 reverse share split) approved by its board and shareholders to address the bid price deficiency.
• The Nasdaq letter has no immediate effect on the listing of ordinary shares or warrants.

Negatives

• The company's ordinary shares traded below the minimum $1.00 bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
• The Nasdaq hearings panel will consider this bid price deficiency in its decision regarding continued listing.
• There is no assurance that the company will successfully meet the terms of its compliance plan or achieve and maintain compliance with the Equity Standard of the Nasdaq Capital Market by the September 19, 2025 deadline.
• There is no assurance that the company will successfully meet all other standards for listing on the Nasdaq Capital Market even if it initially restores compliance by the deadline.
• The company may not be successful in effecting transactions that raise its shareholders' equity to the minimum level of $2.5 million required by September 19, 2025.
• The company may encounter other difficulties in maintaining compliance with the $2.5 million minimum shareholders' equity level or other Nasdaq listing standards on an ongoing basis.

Risks

• Failure to successfully meet the terms of the compliance plan and/or achieve and maintain compliance with the Equity Standard of the Nasdaq Capital Market by the September 19, 2025 deadline.
• Failure to successfully meet all other standards for listing on the Nasdaq Capital Market even if initial compliance is restored by the deadline.
• Inability to successfully effect transactions that raise the company's shareholders' equity to the minimum level of $2.5 million required to meet the Equity Standard by September 19, 2025.
• Potential difficulties in maintaining compliance with the $2.5 million minimum shareholders' equity level or other Nasdaq listing standards on an ongoing basis.
• Actual future events differing materially from forward-looking statements due to various factors.

Future Outlook

The company expects to regain compliance with the Nasdaq bid price requirement after the 1-for-15 reverse share split, assuming the ordinary shares close above $1.00 for at least 10 consecutive trading days following the split. The company also aims to achieve at least $2.5 million in shareholders' equity to meet the Nasdaq Equity Standard by September 19, 2025. However, there is no assurance that these compliance goals will be met or maintained.

Management Comments

• The Company intends to effect a reverse share split to remedy the bid price deficiency.

Industry Context

This announcement is specific to Silexion Therapeutics Corp's compliance with Nasdaq listing rules, which are standard for publicly traded companies. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess against global benchmarks. The compliance rules ($1.00 bid price, $2.5 million equity) are standard Nasdaq requirements for continued listing.

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience a 1-for-15 reverse share split, reducing the number of shares held but increasing the per-share price. Face ongoing risk of delisting if compliance is not met, which could significantly impact liquidity and share value.
• Nasdaq: The company's actions are directly aimed at satisfying Nasdaq's listing requirements to maintain its presence on the exchange.

Next Steps

• Effect a 1-for-15 reverse share split after the close of trading on July 28, 2025.
• Begin trading on a reverse split-adjusted basis on the Nasdaq Capital Market at the open of the market on July 29, 2025.
• Maintain a closing bid price above $1.00 for a minimum of 10 consecutive trading days following the reverse split to regain compliance.
• Achieve at least $2.5 million of shareholders' equity to meet the Nasdaq Equity Standard by September 19, 2025.

Key Dates

Recommendation

Keywords

Silexion Therapeutics, SLXN, Nasdaq, delisting, bid price deficiency, reverse stock split, reverse share split, compliance, Nasdaq Capital Market, equity standard, SEC filing, 8-K